Clinical trials: Bladder Hyperactivity
Overactive Bladder
Utilization of the BIOWAVE Device to Treat Overactive Bladder
Demonstrate a response to stimulation of the posterior tibial nerve using the Biowave device and a microneedle patch electrode in patients with overactive bladder symptoms.
- Trial name
- OAB (NCT01848366)
- Testing
- Biowave Treatment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Kenneth Peters, MD
Overactive Bladder (OAB), Urinary Urgency
Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder
The goal of this clinical trial is to learn if using a portable nerve stimulation (TENS) device during daily life works to reduce overactive bladder (OAB) symptoms in adults aged 18 to 65.
- Trial name
- NCT07540273
- Testing
- Ambulatory Transcutaneous Tibial Nerve Stimulation, Conventional Clinic-Based Transcutaneous Tibial Nerve Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- SEZGIN
Overactive Bladder, Urinary Incontinence
Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
The objective is to evaluate the efficacy and safety of mirabegron to treat urinary incontinence in children with Overactive Bladder that are refractory and/or intolerant to antimuscarinics.
- Trial name
- Mirabegron (NCT02468830)
- Testing
- mirabegron
- Volunteers
- 58 people
- Sponsor
- CHU de Quebec-Universite Laval
Overactive Bladder (OAB)
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
- Trial name
- PILLAR (NCT02216214)
- Testing
- Mirabegron
- Where
- 120 sites in United States, Canada
- Volunteers
- 888 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder in Parkinson's Disease
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.
- Trial name
- URGE-PD (NCT01018264)
- Testing
- solifenacin succinate (VESIcare)
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of South Florida
Overactive Bladder
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
- Trial name
- NCT00501267
- Testing
- solabegron and oxybutynin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overactive Bladder, Urgency-Frequency
Comparison of Motor and Sensory Response With Interstim Stimulation
Sacral nerve stimulation (SNS) implantation is a minimally invasive procedure which has current FDA approval for urinary urge incontinence, urgency-frequency syndrome and non-obstructive urinary retention, and has been available…
- Trial name
- NCT00943904
- Testing
- Interstim implant for SNS
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of California, Irvine
Urinary Frequency/Urgency
Development of Novel Cystometrics for Overactive Bladder
Urinary urgency is the key symptom of overactive bladder (OAB). A critical barrier in understanding OAB is the lack of a method to separate urgency that derives directly from bladder filling or what we term "tension sensor…
- Trial name
- NCT02060214
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Overactive Bladder
MIrabegron With oveRACtive bLadder Symptoms in mEn
The proportion of male patients who participated in the phase III study of mirabegron was about 28% and the data on the efficacy and safety of mirabegron in Korean male OAB patients have limits.
- Trial name
- NCT02361502
- Testing
- mirabegron
- Where
- 15 sites in South Korea
- Volunteers
- 462 people
- Sponsor
- Seoul National University Hospital
Overactive Bladder Syndrome
Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females
The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome.
- Trial name
- NCT01042119
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Zurich
Urinary Incontinence, Overactive Bladder
Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study
At an academic tertiary referral center, patients with pelvic floor dysfunction, scheduled for outpatient cystoscopy or urodynamic testing will be asked to participate in the study.
- Conditions
- Urinary Incontinence, Overactive Bladder, Pelvic Organ Prolapse, Recurrent Urinary Tract Infections
- Trial name
- NCT01663181
- Where
- Austria
- Volunteers
- 109 people
- Sponsor
- Medical University of Vienna
Overactive Bladder Syndrome
Use of Repris Needle in Bladder Injection
Treatment of overactive bladder (OAB) has been treated successfully by the injection of Botox. The Repris injection needle has a deflection that may assist in injection difficult to reach with standard straight needles.
- Trial name
- NCT04982120
- Testing
- Repris Needle
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Uro-1 Medical
Overactive Bladder
Mirabegron and Urinary Urgency Incontinence
This study is for women diagnosed with urinary urgency incontinence (UUI) or overactive bladder (OAB). Some patients continue to have symptoms even while taking medication for OAB.
- Trial name
- NCT02495389
- Testing
- Mirabegron
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Loyola University
Overactive Bladder
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from…
- Trial name
- NCT01458197
- Testing
- Tarafenacin 0.2 mg, Tarafenacin 0.4 mg
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Overactive Bladder Syndrome
Cyclic Versus Continuous Sacral Neuromodulation for LUTS
This will be a prospective, randomized-controlled multi-site trial comparing cyclic versus continuous sacral neuromodulation (SNM) for OAB.
- Trial name
- NCT06170450
- Testing
- Cyclic SNM, Continuous SNM
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Overactive Bladder
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
This is a Phase IV, prospective, randomized, multi-center study to find risk factors of OAB symptoms relapse in patients who showed therapeutic benefits after 1, 3, or 6 months of treatment with Tolterodine SR and who then…
- Trial name
- NCT00730535
- Testing
- Tolterodine, Tolterodine 6
- Where
- 4 sites in South Korea
- Volunteers
- 173 people
- Sponsor
- KYU-SUNG LEE
Overactive Bladder, Bladder Pain Syndrome
Bladder Botox UTI Antibiotic Prophylaxis
Overactive bladder (OAB) is a common condition with a prevalence of 17% in the general population that significantly affects quality of life.
- Trial name
- NCT06387329
- Testing
- Nitrofurantoin 100 MG
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Idiopathic Overactive Bladder With Urinary Incontinence
Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.
- Trial name
- NCT03109379
- Testing
- Trospium-Releasing Intravesical System (TAR-302-5018)
- Where
- 12 sites in United States
- Volunteers
- 43 people
- Sponsor
- Taris Biomedical LLC
Overactive Bladder Syndrome
Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients
To investigate whether prolonged period of treatment (6 months) can have a better therapeutic outcome than conventional period (3 months) of antimuscarinics.
- Trial name
- NCT01876186
- Testing
- Solifenacin for 12 weeks, Solifenacin for 24 weeks
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Overactive Bladder
The Effects of Pelvic Floor Muscle Training in Women With Overactive Bladdder
The aim of our study is to investigate the effects of pelvic floor muscle training (PFMT) on pelvic floor muscle strength, sexual functions, bladder symptoms and quality of life in women with overactive bladder (OAB).
- Trial name
- NCT04950556
- Testing
- Exercise, Control
- Volunteers
- 40 people
- Sponsor
- Ataturk Training and Research Hospital